All Stories

  1. 18F-FDG PET/CT guided salvage radiotherapy strategies for lymph-nodal relapses in gynecological cancers: SBRT vs ENRT
  2. Repeat gamma knife radiosurgery for recurrent pituitary adenomas
  3. Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques
  4. Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial
  5. A Case of Radiotherapy During Pregnancy for Oropharyngeal Cancer: Long-Term Pediatric Outcome Evaluation and Literature Review
  6. Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series
  7. One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study
  8. Prevention and management of radiotherapy-related toxicities in gynecological malignancies. Position paper on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)
  9. Lymph node oligometastases from prostate cancer: extensive or localized treatments - do we have a basis to decide?
  10. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma
  11. Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer
  12. Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy
  13. Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/10...
  14. Comparing Performances of Predictive Models of Toxicity after Radiotherapy for Breast Cancer Using Different Machine Learning Approaches
  15. Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study
  16. Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience
  17. Real-world validation of Artificial Intelligence-based Computed Tomography auto-contouring for prostate cancer radiotherapy planning
  18. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Ma...
  19. Radiation Therapy for Gestational Trophoblastic Neoplasia: Forward-Looking Lessons Learnt
  20. Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial
  21. Knowledge-based plan optimization for prostate SBRT delivered with CyberKnife according to RTOG0938 protocol
  22. Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study
  23. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study
  24. Granulosa cell tumors (GCTs) of the ovary: What is the role of radiotherapy?
  25. CT radiomic predictors of local relapse after SBRT for lung oligometastases from colorectal cancer: a single institute pilot study
  26. Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
  27. In Regard to Zureick et al.
  28. Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse
  29. Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation
  30. Knowledge-based automatic plan optimization for left-sided whole breast tomotherapy
  31. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients
  32. Could the association of sunitinib and stereotactic ablative radiotherapy lead to abscopal effect in metastatic renal cell carcinoma?
  33. Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study
  34. The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study
  35. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups
  36. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study
  37. Gamma Knife radiosurgery as primary treatment of low-grade brainstem gliomas: A systematic review and metanalysis of current evidence and predictive factors
  38. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis
  39. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study
  40. Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
  41. 933 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD)
  42. Replacing Manual Planning of Whole Breast Irradiation With Knowledge-Based Automatic Optimization by Virtual Tangential-Fields Arc Therapy
  43. In Regard to Wages et al and Leite et al
  44. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost in a Large “Real-Life” Cohort of Consecutive Early-Stage Breast Cancer Patients
  45. Impact of Gastrointestinal Side Effects on Patients’ Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study
  46. Clinical Implementation of Knowledge-Based Automatic Plan Optimization for Helical Tomotherapy
  47. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review
  48. Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
  49. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
  50. Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study)
  51. Residual intra-fraction error in robotic spinal stereotactic body radiotherapy without immobilization devices
  52. Virtual Tangential-fields Arc Therapy (ViTAT) for whole breast irradiation: Technique optimization and validation
  53. How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study
  54. Which oligometastatic PCa should be treated on metastases only?
  55. Concomitant RT to primary and metastases in metastatic PCa
  56. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent
  57. Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group
  58. Patients with MPM treated with high dose RT have higher survival
  59. Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR)
  60. A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups
  61. Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option
  62. European review of treatment strategies in prostate cancer PET positive relapse.
  63. EP-1993 Evidence of CTV underdosing due to anatomical changes during breast Helical Tomotherapy
  64. EP-1553 High-dose hypofractionated helical IG-IMRT in high-risk prostate cancer patients
  65. EP-1303 Hypofractionated adjuvant radiotherapy in elderly low risk breast cancer patients: loss or gain?
  66. EP-1640 Radical radiotherapy in elderly prostate cancer patients: a monoinstitutional experience
  67. PO-0973 Residual intra-fraction error in nonimmobilized patients treated with tracked robotic spinal SBRT
  68. EP-1482 Stereotactic rt in ovarian cancer: multicentric retrospective pooled analysis (MITO-RT project)
  69. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series
  70. Important results from an Italian national survey on prostate cancer diagnosis and treatment.
  71. Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy
  72. Moderately Hypofractionated Helical IMRT, FDG–PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs
  73. Important results from an Italian national survey on prostate cancer diagnosis and treatment.
  74. FDG-PET/CT predictive value in MPM.
  75. Review of current status in prostate cancer PET positive relapse.
  76. EP-1593: Hypofractionated IGRT in high-intermediate and high/very-high risk prostate cancer patients
  77. EP-1221: Hypoxia imaging with 18F-FAZA PET/CT in Radiotherapy Planning for High Grade Gliomas
  78. EP-1191: Outcomes of a mono-institutional experience of IG-IMRT in Glioblastoma
  79. EP-1390: Salvage (postponed) hypofractionated tomotherapy for progressive MPM in patients with intact lungs
  80. Relationship between local relapse and distant metastases in prostate cancer
  81. 11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients
  82. Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR
  83. EP-1319: “Adjuvant”/ radical radiotherapy in prostate cancer patients with synchronous bone oligometastasis
  84. PO-0651: Five year outcome and soft tissue toxicity of breast cancer hypofractionated adjuvant radiotherapy
  85. EP-1159: Hypofractionated adjuvant radiotherapy and concomitant trastuzumab for breast cancer: 5-year results
  86. EP-1318: Is hypofractionation combined to WPRT effective in high risk prostate cancer patients?
  87. EP-1315: Prostate cancer lymph nodal disease: SBRT only or extensive prophylactic irradiation and boost?
  88. PO-0730: The independent benefit deriving from high doses and WPRT in salvage post-prostatectomy radiotherapy
  89. In Regard to Pommier et al
  90. Pros-IT CNR: an Italian prostate cancer monitoring project
  91. Why prostate cancer bone and lymph nodal metastases are different?
  92. Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.043
  93. In Regard to Perrier et al
  94. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I–II Study
  95. radiotherapy for prostate cancer lymph nodal recurrence
  96. EP-1079: Clinical outcomes in locally advanced oropharyngeal cancer 18FDG PET-guided dose escalation IMRT-SIB
  97. PO-0689: Outcome predictors for moderate hypofractionated tomotherapy in Malignant Pleural Mesothelioma
  98. PO-0753: Prospective evaluation of urinary function in patients with prostate cancer treated with RT
  99. EP-1349: Long term results of a phase I-II study of moderate hypofractionated IGRT in prostate cancer
  100. EP-1347: Could “radical” RT be a reasonable choice in bone oligometastatic prostate cancer patients?
  101. 553 Salvage tomotherapy choline PET/CT guided for prostate cancer lymph nodal recurrence
  102. 61 Prophylactic irradiation of pelvic lymph-nodal area after prostatectomy does not increase the risk of second neoplasms: A single institution analysis of 1109 patients with 10 years follow-up
  103. 684 Could “radical” RT be a reasonable therapeutic option in bone oligometastatic prostate cancer patients?
  104. 676 Prospective evaluation of urinary function in patients with prostate cancer treated with external beam radiation therapy
  105. Five-Year Outcomes and Late Toxicity in Prostate Cancer Patients Treated With Moderate Hypofractionated Helical Tomotherapy and Simultaneous Integrated Boost in a Phase 1-2 Study
  106. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
  107. 623 Impact on anxiety and depression of urinary symptoms and incontinence after postprostatectomy radiotherapy in the first year after treatment
  108. PO-0719: Excellent 5 year outcome with image guided moderate hypofractionation in prostate cancer : phase I-II study results
  109. EP-1230: The level of lymphopenia inversely correlates with the risk for late urinary toxicity after WPRTfor prostate cancer
  110. OC-0321: Impact of urinary symptoms and incontinence on anxiety and depression 1 year after postprostatectomy radiotherapy
  111. EP-1157 FDG-PET guided dose escalation with TomoTherapy for locally advanced oropharyngeal cancer
  112. Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients
  113. Salvage therapy of small volume prostate cancer nodal failures: A review of the literature
  114. 11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients
  115. PO-0724: Outcome of Choline PET-CT guided salvage hypofractionated Tomotherapy for lymph-nodal recurrent prostate cancer
  116. High-Dose Moderately Hypofractionated Tomotherapy for Prostate Cancer: 5-Year Results
  117. PD-0316: Forward planned intensity modulated whole breast hypofractionated radiotherapy: results in 500 patients
  118. PO-0713: Salvage post-prostatectomy hypofractionated high dose Tomotherapy with prophylactic whole pelvic irradiation
  119. PO-0717: Five year results of high dose moderately hypofractionated tomotherapy for prostate cancer
  120. EP-1099: PET/CT guided tomotherapy in gynecologic cancers
  121. PO-0701: Toxicity and outcome of recurrent prostate cancer patients treated with 11-C Choline PET/CT-guided tomotherapy
  122. EP-1120: Stereotactic ablative radiotherapy for small lung tumors by means of TomoTherapy: preliminary results and toxicity
  123. PO-0628 TOXICITY PREDICTORS FOR HYPOFRACTIONATED FIMRT IN BREAST CANCER
  124. PET-guided dose escalation tomotherapy in malignant pleural mesothelioma
  125. 868 poster SIMULTANEOUS INTEGRATED BOOST 18FDG-PET BASED HELICAL TOMOTHERAPY IN RADICAL LOCALLY ADVANCED HEAD AND NECK CANCER.
  126. 753 poster EARLY TOXICITY RESULTS OF A FORWARD PLANNED HYPOFRACTIONATED IMRT FOR WHOLE BREAST ADJUVANT TREATMENT
  127. Megavoltage CT Images of Helical Tomotherapy Unit for Radiation Treatment Simulation: Impact on Feasibility of Treatment Planning in a Prostate Cancer Patient with Bilateral Femoral Prostheses
  128. Optimal Acute Toxicity for Concomitant Pelvic Irradiation with Tomotherapy in 153 Prostate Cancer Patients
  129. Hemithoracic Helical Tomotherapy (HT) for Malignant Pleural Mesothelioma (MPM): Early Results of a Dose Escalation Experience
  130. Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients
  131. Benefit on Biochemical Control of Adjuvant Radiation Therapy in Patients with Pathologically Involved Seminal Vesicles after Radical Prostatectomy
  132. Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer
  133. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC)
  134. Androgen Ablation Therapy Does not Increase the Risk of Late Morbidity following 3D-conformal Radiotherapy of Organ-confined Prostate Cancer: The Experience of the European Institute of Oncology
  135. Finding dose–volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer
  136. Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma (NPC)
  137. A GPC method to determine the composition of two component copolymers